HENDERSON, NV / ACCESSWIRE / April 18, 2019 / Cannabis stocks were a sea of red on Monday, weighed down by Aphria Inc. after it swung to a wide loss in the third quarter that outweighed a surge in revenue. This large plunge has created some opportunities on stocks in the sector.
One stock that took a hit but looks positioned to improve is THC Therapeutics, Inc. (THCT). Very recently, the company announced that it has received patent protection for the dHydronator® which can reduce moisture content of cannabis to 10% in only 10-14 hours (normally it takes up to 14 days). The US patent office has ALL 20 claims for The dHydronator®. The dHydronator® also destroys harmful surface contaminants & pathogens. The term of the patent provides 20 years of protection on the scalable intellectual property for the dHydronator®. This is big news from THCT.
Today we are highlighting: THC Therapeutics, Inc. (THCT), Organigram Holdings Inc. (OGRMF), Sorrento Therapeutics, Inc. (SRNE), Abattis Bioceuticals Corp. (ATTBF) and Terra Tech Corp. (TRTC).
THC Therapeutics, Inc. (THCT) (Market Cap: $110.195M; Share Price: $8.25) has developed a sanitizing herb dryer, The dHydronator®. Their laboratory-proven product is specifically designed for drying and sanitizing freshly harvested cannabis and herbs. THCT's product has been tested by two independent laboratories. The testing covered over 6 strains and 9 independent tests to confirm the findings.
As we mentioned earlier, the US patent office has accepted ALL 20 claims for The dHydronator®. The company recently received patent protection for the dHydronator®. Start your research today on THCT.
Organigram Holdings Inc. (OGRMF) (Market Cap: $861.517M; Share Price: $6.65), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced its results for the second quarter ended February 28, 2019 ("Q2" or "Q2 2019"). The Q2 2019 includes the first full quarter of adult-use recreational sales for the company. Highlights include:
- Record net revenue of $26.9 million or more than double the net revenue of Q1-2019
- Adjusted gross margin of $16.0 million or 60%
- Adjusted EBITDA of $13.3 million or adjusted EBITDA margin of 49%
Organigram Holdings Inc. recently announced the company has entered into an agreement with 1812 Hemp, a New Brunswick based industrial hemp research company to secure supply and support research and development on the genetic improvement of hemp through traditional plant breeding methods. Under the terms of the agreement, Organigram will have access to a secure supply of hemp flower which contains significant levels of cannabidiol (CBD cultivars ranging from 4% to 8%).
OrganiGram Holdings Inc., through its subsidiaries, produces and sells dried cannabis and cannabis oil in Canada. It also offers wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis oils to retailers and wholesalers. The company also exports its products. It sells its products online, as well as through phone orders. OrganiGram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.
Sorrento Therapeutics, Inc. (SRNE) (Market Cap: $446.23M; Share Price: $3.89) announced recently that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin (RTX) for multiple life-threatening cardiovascular disorders, including IND enabling toxicology and proof-of-principle animal studies. It announced today that it has established a new business unit to focus on the market potential for its innovative water soluble cannabidiol (CBD) formulation technology.
Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia.
Abattis Bioceuticals Corp. (ATTBF) (Market Cap: $20.864M; Share Price: $0.04885) recently announced that its wholly-owned subsidiary, 1185277 B.C. Ltd., has entered into a share purchase agreement to acquire Pro Natura BV ("Pro Natura"), a privately held nutraceutical company based in Oisterwijk, Netherlands.
The Agreement provides for the acquisition of 100% of Pro Natura's outstanding shares from Catalyst Investment Capital Corp. ("Catalyst") in exchange for the payment of €6,684,200 to Catalyst, which will be paid as follows: (i) €2,000,000 on closing; (ii) €2,220,000 one year following closing; and (iii) €2,464,200 two years following closing. The Acquisition Subsidiary has also agreed to pay Catalyst (i) a €5,000,000 milestone payment within two years of Abattis CBD products being launched through Pro Natura's sales and (ii) a €4,000,000 milestone payment within two years of launch of sales of Abattis' proprietary product, Comfort, through Pro Natura's sales channels. The Acquisition Subsidiary's obligation to make these milestone payments will expire within three years from closing of the Agreement.
Abattis Bioceuticals Corp., a biotechnology company, researches, develops, licenses, and markets ingredients and formulas for use in the biopharma, nutraceutical, cosmetic, and animal nutrition markets in Canada. It is also involved in the possession of cannabis and related active ingredients, as well as the production of extracts and marketing services. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012.
It is positioned to be a leader in the cannabis industry as a fully integrated medicinal cannabis company. In addition to the company's flagship cultivation asset located on British Columbia's Gabriola Island, Abattis is aggressively building its portfolio of assets including through the acquisition of 140 genetic strains and a robust portfolio of fertilizers and nutrients, custom formulated for the emerging cannabis market. Abattis has also solidified key investments into XLABS Therapeutics (ONT) Inc., building one of Canada's largest cannabinoid manufacturing labs, as well as blockchain service and cryptocurrency platforms focused solely on cannabis product and service transactions.
Terra Tech Corp. (TRTC) (Market Cap: $77.770M; Share Price: $0.7575), a vertically integrated cannabis-focused agriculture company, announced last week it has secured a permit to manufacture cannabis for the adult use market at its 15,000 square foot extraction facility in Reno, which is 50% owned by NuLeaf, from the State of Nevada.
Terra Tech Corp. operates as a vertically integrated cannabis-focused agriculture company. The company operates in three segments: Herbs and Produce Products; Cannabis Dispensary, Cultivation and Production; and Real Estate and Construction. The Herbs and Produce Products segment offers hydroponic herbs and leafy greens products. The Cannabis Dispensary, Cultivation and Production segment operates medical marijuana retail and adult use dispensaries under the Blüm brand.
It operates through multiple subsidiary businesses including: Blüm, IVXX Inc., Edible Garden, and MediFarm LLC. Blüm's retail and medical cannabis facilities provide the highest quality medical cannabis to patients who are looking for alternative treatments for their chronic medical conditions as well as premium cannabis to the adult-use market in Nevada and California. Blüm offers a broad selection of cannabis products including; flowers, concentrates and edibles through its multiple California and Nevada locations. IVXX, Inc. is a wholly-owned subsidiary of Terra Tech that produces cannabis-extracted products for regulated medical cannabis dispensaries throughout California. The company's wholly-owned subsidiary, Edible Garden, cultivates a premier brand of local and sustainably grown hydroponic produce, sold through major grocery stores such as ShopRite, Walmart, Ahold, Aldi, Meijer, Kroger, Stop & Shop and others nationwide. Terra Tech'sMediFarm LLC subsidiaries are focused on medical and adult-use cannabis cultivation and permitting businesses throughout Nevada.
Priyanka Goel, CFA
This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to a three-month term consulting agreement with THCT dated 2/14/18. The agreement calls for 50,000 restricted shares of THCT per month. This agreement has been amended to $20,000 per month, and 55,000 shares per month and extended for twelve months ending 3/18/2020. All payments were made directly by THC Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. THCT was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
Full Legal Disclaimer Click Here.
Company Name: ACR Communication LLC.
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communication LLC
View source version on accesswire.com: